Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144


Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases.

Wong WB, Wu N, Yang E, Davies J, Chae YK.

J Oncol Pract. 2019 Sep 11:JOP1900166. doi: 10.1200/JOP.19.00166. [Epub ahead of print]


Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review.

Chae YK, Saleem N, Roh Y, Bilal H, Viveiros P, Sukhadia B, Lin X, Sheikh MM, Park LC.

BMC Cancer. 2019 Jul 30;19(1):748. doi: 10.1186/s12885-019-5934-4.


Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.

Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O.

Clin Cancer Res. 2019 Jul 12. doi: 10.1158/1078-0432.CCR-18-4049. [Epub ahead of print]


Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial.

Carneiro BA, Konda B, Costa RB, Costa RLB, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ.

J Clin Endocrinol Metab. 2019 Jul 5. pii: jc.2019-00600. doi: 10.1210/jc.2019-00600. [Epub ahead of print]


Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W.

J Thorac Oncol. 2019 Jun 22. pii: S1556-0864(19)30496-4. doi: 10.1016/j.jtho.2019.06.016. [Epub ahead of print]


Three-Dimensional Digitalized Surface and Volumetric Analysis of Posterior Prefabricated Zirconia Crowns for Children.

Lee H, Chae YK, Lee HS, Choi SC, Nam OH.

J Clin Pediatr Dent. 2019;43(4):231-238. doi: 10.17796/1053-4625-43.4.2. Epub 2019 May 16.


Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ.

Oncologist. 2019 Jun;24(6):820-828. doi: 10.1634/theoncologist.2018-0433. Epub 2019 Mar 13.


Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma.

Chae YK, Anker JF, Oh MS, Bais P, Namburi S, Agte S, Giles FJ, Chuang JH.

Sci Rep. 2019 Mar 1;9(1):3235. doi: 10.1038/s41598-019-39594-4.


Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S.

Breast. 2019 Apr;44:29-32. doi: 10.1016/j.breast.2018.12.010. Epub 2018 Dec 20.


An easy way to secure catheter in position during marsupialization procedure.

Chae YK, Nam OH, Kim MS, Lee HS, Kwon YD, Choi SC.

J Stomatol Oral Maxillofac Surg. 2019 Jun;120(3):244-249. doi: 10.1016/j.jormas.2018.12.007. Epub 2018 Dec 15.


Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.

Chae YK, Davis AA, Raparia K, Agte S, Pan A, Mohindra N, Villaflor V, Giles F.

Clin Lung Cancer. 2019 Mar;20(2):88-96.e6. doi: 10.1016/j.cllc.2018.09.008. Epub 2018 Sep 25.


A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.

Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A.

Clin Cancer Res. 2019 Jan 15;25(2):496-505. doi: 10.1158/1078-0432.CCR-18-2014. Epub 2018 Oct 16.


Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy.

Donaldson M, Owen JL, Chae YK, Choi JN.

Front Oncol. 2018 Sep 25;8:405. doi: 10.3389/fonc.2018.00405. eCollection 2018.


Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.

Chae YK, Oh MS.

J Thorac Oncol. 2019 Jan;14(1):16-24. doi: 10.1016/j.jtho.2018.09.022. Epub 2018 Oct 6. Review.


Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer.

Oh MS, Chae YK.

J Immunother. 2019 Feb/Mar;42(2):51-54. doi: 10.1097/CJI.0000000000000244.


Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.

Chae YK, Chiec L, Adney SK, Waitzman J, Costa R, Carneiro B, Matsangou M, Agulnik M, Kopp P, Giles F.

Oncotarget. 2018 Jun 15;9(46):28281-28289. doi: 10.18632/oncotarget.25606. eCollection 2018 Jun 15. Review.


Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.

Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK.

Oncotarget. 2018 Apr 24;9(31):22137-22146. doi: 10.18632/oncotarget.25154. eCollection 2018 Apr 24.


Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).

Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F.

J Immunother Cancer. 2018 May 16;6(1):39. doi: 10.1186/s40425-018-0349-3. Review.


Immune checkpoint pathways in non-small cell lung cancer.

Chae YK, Arya A, Iams W, Cruz M, Mohindra N, Villaflor V, Giles FJ.

Ann Transl Med. 2018 Mar;6(5):88. doi: 10.21037/atm.2017.09.30. Review.


Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA.

Clin Cancer Res. 2018 Jun 15;24(12):2732-2739. doi: 10.1158/1078-0432.CCR-18-0332. Epub 2018 Mar 20.


Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma.

Chae YK, Anker JF, Bais P, Namburi S, Giles FJ, Chuang JH.

Oncotarget. 2017 Dec 15;9(8):7949-7960. doi: 10.18632/oncotarget.23742. eCollection 2018 Jan 30.


Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).

Chae YK, Chang S, Ko T, Anker J, Agte S, Iams W, Choi WM, Lee K, Cruz M.

Sci Rep. 2018 Feb 13;8(1):2918. doi: 10.1038/s41598-018-21061-1.


Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.

Chae YK, Choi WM, Bae WH, Anker J, Davis AA, Agte S, Iams WT, Cruz M, Matsangou M, Giles FJ.

Sci Rep. 2018 Jan 18;8(1):1023. doi: 10.1038/s41598-018-19454-3.


Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.

Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M.

Clin Lung Cancer. 2018 May;19(3):280-288.e4. doi: 10.1016/j.cllc.2017.12.007. Epub 2017 Dec 21.


Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Taxter T, Kuzel TM, Fan A, Chae YK, Cristofanilli M, Hussain MH, Abdulkadir SA, Giles FJ.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14.


Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.

Chae YK, Galvez C, Anker JF, Iams WT, Bhave M.

Cancer Treat Rev. 2018 Feb;63:116-121. doi: 10.1016/j.ctrv.2017.12.004. Epub 2017 Dec 8. Review.


Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V, Cristofanilli M, Giles F.

Oncotarget. 2017 Aug 1;8(59):100863-100898. doi: 10.18632/oncotarget.19809. eCollection 2017 Nov 21. Review.


Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.

Chae YK, Oh MS, Giles FJ.

Oncologist. 2018 Apr;23(4):410-421. doi: 10.1634/theoncologist.2017-0354. Epub 2017 Dec 14. Review.


Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ.

Mol Cancer Ther. 2017 Dec;16(12):2645-2655. doi: 10.1158/1535-7163.MCT-17-0597. Review.


Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer.

Pai SG, Carneiro BA, Chae YK, Costa RL, Kalyan A, Shah HA, Helenowski I, Rademaker AW, Mahalingam D, Giles FJ.

J Gastrointest Oncol. 2017 Oct;8(5):858-866. doi: 10.21037/jgo.2017.06.20.


A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.

Mota JM, Collier KA, Barros Costa RL, Taxter T, Kalyan A, Leite CA, Chae YK, Giles FJ, Carneiro BA.

Oncotarget. 2017 Jun 13;8(51):89284-89306. doi: 10.18632/oncotarget.18467. eCollection 2017 Oct 24. Review.


Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ.

Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15.


Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review.

Chae YK, Wang S, Nimeiri H, Kalyan A, Giles FJ.

Oncotarget. 2017 Jun 3;8(34):57889-57897. doi: 10.18632/oncotarget.18361. eCollection 2017 Aug 22.


Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, Giles FJ.

Cancer Manag Res. 2017 Jun 14;9:207-213. doi: 10.2147/CMAR.S136818. eCollection 2017. Review.


Relationship between recombinant protein expression and host metabolome as determined by two-dimensional NMR spectroscopy.

Chae YK, Kim SH, Markley JL.

PLoS One. 2017 May 9;12(5):e0177233. doi: 10.1371/journal.pone.0177233. eCollection 2017.


Wnt/beta-catenin pathway: modulating anticancer immune response.

Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ.

J Hematol Oncol. 2017 May 5;10(1):101. doi: 10.1186/s13045-017-0471-6. Review.


Nodal Signaling as a Developmental Therapeutics Target in Oncology.

Kalyan A, Carneiro BA, Chandra S, Kaplan J, Chae YK, Matsangou M, Hendrix MJC, Giles F.

Mol Cancer Ther. 2017 May;16(5):787-792. doi: 10.1158/1535-7163.MCT-16-0215. Review.


Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.

Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, Platanias LC, Gradishar W, Giles FJ, Cristofanilli M.

Mol Cancer Ther. 2017 Jul;16(7):1412-1420. doi: 10.1158/1535-7163.MCT-17-0061. Epub 2017 Apr 26.


Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.

Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ.

Cancer Treat Rev. 2017 Apr;55:10-15. doi: 10.1016/j.ctrv.2017.02.006. Epub 2017 Feb 22. Review.


Developmental Therapeutics Implications of Next-Generation Sequencing in Human Herpesvirus 8-Negative Castleman Disease.

Zhou XA, Chae YK, Giles FJ.

JAMA Dermatol. 2017 May 1;153(5):381-382. doi: 10.1001/jamadermatol.2016.5555. No abstract available.


Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ.

Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532. Review.


Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ.

Cancer Treat Rev. 2017 Feb;53:111-119. doi: 10.1016/j.ctrv.2016.12.010. Epub 2017 Jan 5. Review.


Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.

Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ.

Oncotarget. 2017 Feb 28;8(9):16052-16074. doi: 10.18632/oncotarget.14109. Review.


Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.

Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M.

Oncotarget. 2017 Feb 14;8(7):12417-12432. doi: 10.18632/oncotarget.13778. Review.


Repurposing metformin for cancer treatment: current clinical studies.

Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, Giles F.

Oncotarget. 2016 Jun 28;7(26):40767-40780. doi: 10.18632/oncotarget.8194. Review.


A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.

Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F.

Cancer Immunol Immunother. 2017 Jan;66(1):25-32. doi: 10.1007/s00262-016-1913-7. Epub 2016 Oct 19.


Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.

Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ.

Oncotarget. 2016 Oct 4;7(40):65364-65373. doi: 10.18632/oncotarget.11692.


Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.

Chae YK, Pan A, Davis AA, Mohindra N, Matsangou M, Villaflor V, Giles F.

Clin Lung Cancer. 2017 Mar;18(2):132-140. doi: 10.1016/j.cllc.2016.07.004. Epub 2016 Jul 9. Review.


FGFR3-TACC3 fusion in solid tumors: mini review.

Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK, Giles FJ.

Oncotarget. 2016 Aug 23;7(34):55924-55938. doi: 10.18632/oncotarget.10482. Review.


Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ.

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Review.


Supplemental Content

Support Center